Activation of neurotensin receptor type 1 decreases hyperlocomotion and glycogen synthase kinase-3 activity
Chelsea A. Vadnie(Mayo Clinic), Doo‐Sup Choi(Mayo Clinic), Jennifer Ayers-Ringler(Mayo Clinic), Mario J. Hitschfeld(Mayo Clinic), Osama A. Abulseoud(Mayo Clinic in Arizona), Sun Choi(Mayo Clinic)
Cited by 0
Related Papers
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|Journal of Clinical Oncology|2008|377
Non-Stem Cell Origin for Oligodendroglioma
|Cancer Cell|2010|239
Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders
|Nature Mental Health|2023|235
Asymmetry-Defective Oligodendrocyte Progenitors Are Glioma Precursors
|Cancer Cell|2011|227